Volume 24, Issue 2 - Risk Management

A shot at demystifying the risk management plan for medical writers

Author: Sandra Götsch -Schmidt

Abstract

Download the full article

References

1. Guideline on good pharmacovigilance practices (GVP) Module V – Risk management systems (Rev 1). EMA/838713/2011 Rev 1. European Medicines Agency [2014 Apr 15; cited 2015 Jan 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf
2. Key C, Mulchrone B, Wai K. The value of reviewing existing EU risk management plans. RAJ Pharma. 2010;79–84.
3. Guidance on format of the risk-management plan in the European Union. European Medicines Agency [cited 2015 Jan 23]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000360.jsp
4. Richardson SJ. Strategic medical writing in the post-authorisation phase. Med Writing. 2014;23(4):267–72.
5. ICH harmonised tripartite guideline: Pharmacovigilance planning E2E. International Conference on Harmonisation [2004; cited 2015 Feb 1]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf
6. Chamberlain James L, Creuwels LAJM, Davies M. Risk management plans – new challenges for a new era. Regulatory Rapporteur. 2014;11(6):4–7.
7. Guideline on good pharmacovigilance practices (GVP) Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (Rev 1). EMA/204715/2012 Rev 1. European Medicines Agency [2014 Apr 15; cited 2015 Jan 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162051.pdf
8. Orleans-Lindsay J. Appendix 5: The new EU risk management plan. In: Pharmacovigilance medical writing: A good practice guide. Chichester, UK: Wiley-Blackwell; 2012, p. 215–25.